1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Pathfinder Cell Therapy, Inc. (PFND) - Financial and Strategic SWOT Analysis Review

Summary

Pathfinder Cell Therapy, Inc. (Pathfinder) is a regenerative medicine company that develops novel based therapies. The company has discovered a new mammalian cell type which is able to stimulate damaged tissues to regenerate without the pathfinder cells. Its PCs are isolated from both rat and human pancreas and human kidney. Pathfinder’s PCs has three different animal models of diabetes, cardiac ischemia, and renal reperfusion injury. The company’s animal models are tested from both rat and human sources. Its novel cell-based therapies are used to treat diabetes, renal disease, myocardial infarction, and other diseases characterized by organ-specific cell damage. Pathfinder is headquartered in Cambridge, Massachusetts, the US.

Pathfinder Cell Therapy, Inc. Key Recent Developments

May 15, 2015: Pathfinder Cell Therapy Reports Q1 2015 Results
Mar 31, 2015: Pathfinder Cell Therapy Reports 2014 Results

This comprehensive SWOT profile of Pathfinder Cell Therapy, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Table Of Contents

Pathfinder Cell Therapy, Inc. (PFND) - Financial and Strategic SWOT Analysis Review
Table of Contents

Section 1 - About the Company

Pathfinder Cell Therapy, Inc. - Key Information
Pathfinder Cell Therapy, Inc. - Overview
Pathfinder Cell Therapy, Inc. - Key Employees
Pathfinder Cell Therapy, Inc. - Key Employee Biographies
Pathfinder Cell Therapy, Inc. - Key Operational Heads
Pathfinder Cell Therapy, Inc. - Major Products and Services
Pathfinder Cell Therapy, Inc. - History
Pathfinder Cell Therapy, Inc. - Company Statement
Pathfinder Cell Therapy, Inc. - Locations And Subsidiaries
Pathfinder Cell Therapy, Inc. - Key Manufacturing facilities
Head Office
Other Locations and Subsidiaries

Section 2 - Company Analysis

Pathfinder Cell Therapy, Inc. - Business Description
Pathfinder Cell Therapy, Inc. - Corporate Strategy
Pathfinder Cell Therapy, Inc. - SWOT Analysis
SWOT Analysis - Overview
Pathfinder Cell Therapy, Inc. - Strengths
Pathfinder Cell Therapy, Inc. - Weaknesses
Pathfinder Cell Therapy, Inc. - Opportunities
Pathfinder Cell Therapy, Inc. - Threats
Pathfinder Cell Therapy, Inc. - Key Competitors

Section 3 - Company Financial Performance Charts

Pathfinder Cell Therapy, Inc. - Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 - Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer


Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Pathfinder Cell Therapy, Inc., Key Information
Pathfinder Cell Therapy, Inc., Key Ratios
Pathfinder Cell Therapy, Inc., Share Data
Pathfinder Cell Therapy, Inc., Major Products and Services
Pathfinder Cell Therapy, Inc., History
Pathfinder Cell Therapy, Inc., Key Employees
Pathfinder Cell Therapy, Inc., Key Employee Biographies
Pathfinder Cell Therapy, Inc., Key Operational Heads
Pathfinder Cell Therapy, Inc., Other Locations
Pathfinder Cell Therapy, Inc., Subsidiaries
Pathfinder Cell Therapy, Inc., Key Manufacturing facilities
Pathfinder Cell Therapy, Inc., Key Competitors
Pathfinder Cell Therapy, Inc., SWOT Analysis
Pathfinder Cell Therapy, Inc., Ratios based on current share price
Pathfinder Cell Therapy, Inc., Annual Ratios
Pathfinder Cell Therapy, Inc., Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Pathfinder Cell Therapy, Inc., Performance Chart
Pathfinder Cell Therapy, Inc., Ratio Charts

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Review, H1 2016

C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Review, H1 2016

  • $ 3 500
  • Company report
  • June 2016
  • by Global Markets Direct

C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - ...

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2016

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2016

  • $ 3 500
  • Company report
  • June 2016
  • by Global Markets Direct

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ...

Canavan Disease - Pipeline Review, H1 2016

Canavan Disease - Pipeline Review, H1 2016

  • $ 2 000
  • Company report
  • May 2016
  • by Global Markets Direct

Canavan Disease - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Canavan Disease - Pipeline Review, H1 2016’, provides an overview of the Canavan Disease pipeline landscape. The report ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.